

CSD/NSE&BSE/2025-26
August 27, 2025

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001
Scrip Code: 543064

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Scrip Symbol: COHANCE

Dear Sir/ Madam,

Sub: Disclosure under the SEBI (Prohibition of Insider Trading) Regulations, 2015

We forward herewith disclosure (Form C) received from Dr. V Prasada Raju, Managing Director of the Company, under the SEBI (Prohibition of Insider Trading) Regulation, 2015 with respect to sale of shares of the Company.

This is for your information and record.

Thanking you.

Yours faithfully,
For **Cohance Lifesciences Limited**
(Formerly, Suven Pharmaceuticals Limited)

Kundan Kumar Jha
Company Secretary, Compliance Officer and Head-Legal

Encl: as above

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad
Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road,
Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com



Date: August 26, 2025

To
The Compliance Officer
Cohance Lifesciences Limited
(Formerly Suven Pharmaceuticals Limited)
202, A-Wing, 2nd Floor, Galaxy Towers,
Plot No.1, Hyderabad Knowledge City,
TSIIC Raidurg, Hyderabad,
Telangana 500081

Sub: Disclosure of Sale of Shares under SEBI (Prohibition of Insider Trading) Regulations, 2015

Dear Sir,

Please find annexed disclosure in Form - C, as prescribed under the SEBI (Prohibition of Insider Trading) Regulations, 2015 with respect to sale of 6,00,000 shares of the Company, executed on August 26, 2025.

This transaction was undertaken primarily to repay the loan availed for exercising stock options under the ESOP scheme and the associated tax obligations, and additionally to discharge certain personal liabilities. Therefore, the transaction was to discharge my personal financial obligations.

I continue to remain dedicated towards our shared strategic vision of becoming a leading technology led CDMO with a global footprint.

This disclosure is being made to ensure complete transparency with the stock exchanges and all stakeholders as per the applicable regulations.

Please take this disclosure on record and arrange for the necessary regulatory filings.

Thanking you.

Yours faithfully,


Dr. V Prasada Raju

Encl: as above.

FORM – C
SEBI (Prohibition of Insider Trading) Regulations, 2015
[Regulation 7 (2) read with Regulation 6(2) – Continual disclosure]

Name of the company: **Cohance Lifesciences Limited (Formerly, Suven Pharmaceuticals Limited)**
ISIN of the company: **INE03QK01018**

Details of change in holding of Securities of Promoter, Member of the Promoter Group, Designated Person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2).


Name, PAN No., CIN/DIN, & address with contact nos.	Category of Person (Promoter/ member of the promoter group/ designated person/ Directors/ Immediate relative to/others etc.)	Securities held prior to acquisition/ disposal		Securities acquired/ Disposed				Securities held post acquisition/ disposal		Date of allotment advice/ acquisition of shares/ sale of shares specify		Date of intimation to company	Mode of acquisition/ disposal (on market purchase/ public rights/ preferential offer / off market/ Inter-se Transfer, ESOPs etc	Exchange on which the trade was executed
		Type of security (For eg. – Shares, Warrants, Convertible Debentures etc.)	No. and % of share- holding	Type of security (For eg. – Shares, Warrants, Convertible Debentures etc.)	No.	Value	Transaction Type (Buy/ Sale/ Pledge/ Revoke/ Invoke)	Type of security (For eg. – Shares, Warrants, Convertible Debentures etc.)	No. and % of Share- holding	From	To			
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Dr. Venkata Naga Kali Vara Prasada Raju Vetukuri, PAN: ABPPV8600F, DIN: 07267366 Address: 6B 800, Lodha Bellezza, Eden Square 4th Phase, Kukatpally, Medchal-Malkajgiri 500072, Telangana, India Contact No. 91-40-2354 9414	Managing Director	Shares	7,13,259 0.19%	Shares	6,00,000	Rs. 52.82 Crores	Sale	Shares	1,13,259 0.03%	26-08- 2025	26-08- 2025	26-08-2025	On-market	NSE/ BSE

Note: (i) "Securities" shall have the meaning as defined under regulation 2(1)(i) of SEBI (Prohibition of Insider Trading) Regulations, 2015.
(ii) Value of transaction excludes taxes/brokerage/any other charges

Details of trading in derivatives on the securities of the company by Promoter, member of the promoter group, designated person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2).

Trading in derivatives (Specify type of contract, Futures or Options etc)						Exchange on which the trade was executed
Type of contract	Contract specifications	Buy		Sell		
		Notional Value	Number of units (contracts * lot size)	Notional Value	Number of units (contracts * lot size)	
16	17	18	19	20	21	22
Nil	Nil	Nil	Nil	Nil	Nil	Nil

Note: In case of Options, notional value shall be calculated based on Premium plus strike price of options.


Name & Signature: Dr. Venkata Naga Kali Vara Prasada Raju Vetukuri
Designation: Managing Director
Date: August 26, 2025
Place: Hyderabad